Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal trophic factor
- Development stage
- Phase 2
- Lead developer
- Stem Cell Institute Panama
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Hormones & Growth Factors → Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation, Intraarticular, Intravenous, Intrathecal
01
Overview
Mesenchymal Trophic Factor (MTF) refers to a biologically active preparation derived from the secretome of mesenchymal stem cells (MSCs), containing a blend of free healing molecules, extracellular vesicles, and exosomes. These factors include cytokines and growth factors such as prostaglandin E2 (PGE2), fibroblast growth factor (FGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor A (VEGF-A), hepatocyte growth factor (HGF), interleukins, transforming growth factor beta (TGF-β), and others. MTF is designed to harness the paracrine effects of MSCs—primarily anti-inflammatory and regenerative actions—without introducing live cells. The mechanism involves modulation of immune responses, reduction of inflammation, promotion of tissue repair/regeneration across multiple tissues including skin, nerves, cartilage, blood vessels and bone. Early research suggests that MTF may have therapeutic potential in conditions characterized by inflammation or tissue damage[1][3][5].
- Brand names
- Golden Cells
- Other names
- mesenchymal trophic factorsMTFstem cell secretome
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)FGFR1 (Fibroblast growth factor receptor 1)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on mesenchymal trophic factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal trophic factor.